

This policy applies to **all project requests** for or on behalf of MaGIC resulting from the “friendship network” with or without MaGIC data.

All principal investigators on behalf of the project team are required to follow the applicable process.

REFERENCE

MaGIC Chair	Lindsay Frazier
MaGIC Vice Chairs	Aditya Bagrodia, Michelle Lockley, James Nicholson
Cooperative Group Chairs	Luiz Fernando Lopes, Brazilian Society of Pediatric Oncology (SOBOPE)
	Lindsay Frazier, the Children's Oncology Group (COG)
	Sara Stoneham, the Clinical Research UK Clinical Trials Unit (CRCTU)
	Praful Ravi, Dana-Farber Cancer Institute (DFCI)
	Monica Terenziani, Fondazione IRCCS Istituto Nazionale dei Tumori
	Robert Huddart, the Medical Research Council (MRC)
	Allan Covens, NRG Oncology
	Brice Fresneau, the Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent (SFCE)
	Samuel Funt, Memorial Sloan-Kettering Cancer Center (MSKCC)
	Girish Chinnaswamy, Tata Memorial Hospital
MaGIC Project Reviewers	For each project, the Executive Committee will assign 2-3 members to review the project

OVERVIEW TABLE

	MaGIC Data Paper	MaGIC Consensus Paper	MaGIC Collaborative Paper	MaGIC Grant Derived Paper
Uses MaGIC Data	Yes	No	No, may use other data sources	No
MaGIC Project Application required	Yes	No	No	No
Grant/funding	No	No	No	Yes
Feasibility assessment – First	Screening reviews to ensure data are in MaGIC – joint with PCDC and Reviewers	Committee determines feasibility of a consensus paper	No	No

	MaGIC Data Paper	MaGIC Consensus Paper	MaGIC Collaborative Paper	MaGIC Grant Derived Paper
Project Approvers <ul style="list-style-type: none"> <input type="checkbox"/> APPROVED <input type="checkbox"/> APPROVED with request that you consider the feedback <input type="checkbox"/> RESUBMISSION REQUESTED of a revised project addressing the feedback <input type="checkbox"/> REJECTED 	<p>MaGIC Clinical Research Committee and Executive Committee</p> <p>Ensure the data in MaGIC is sufficient for the analyses proposed</p> <p>Reviewers provide a priority recommendation (H-M-L) for review and priority assignment by the EC</p>	<ul style="list-style-type: none"> ▪ MaGIC Committee ▪ MaGIC Executive Committee 	Executive Committee	No approvers
Identifying Authors	<ul style="list-style-type: none"> ▪ Investigator submits preliminary list. ▪ Cooperative Group chairs can add authors to project if their data are being used. 	<p>There is no preset limit to the number of authors. Suggest a smaller group to draft the manuscript and then involve the rest of the group</p> <ul style="list-style-type: none"> ▪ Committee manages author list ▪ EC identifies additional authors to ensure multi-disciplinary and geographically fair representation to really reflect consensus 	Investigator to determine.	Investigator and co-investigators.

	MaGIC Data Paper	MaGIC Consensus Paper	MaGIC Collaborative Paper	MaGIC Grant Derived Paper
Identifying Statisticians	<ul style="list-style-type: none"> Investigator submits preferred statistician. The MaGIC Executive Committee and Cooperative Group chairs will be invited to nominate a statistician to participate in the work and be included on the manuscript (for cooperative group that contributed patients to be included in the proposed project). A lead statistician will be identified 	No data in use.	<ul style="list-style-type: none"> Work Group submits preferred statistician MaGIC Executive Committee can recommend a change or additional statistician A lead statistician will be identified 	Investigator and Cooperative Group chairs.
Manuscript Titles	Include MaGIC in the title	Include MaGIC in the title	MaGIC not in the title	MaGIC not in the title.
MaGIC Acknowledgement Paragraph	Yes	Yes	Consider including	Yes
Abstract/ Manuscript review	From the identified author list, the Executive Committee will indicate 2-3 people responsible for reviewing abstract and manuscript	MaGIC Executive Committee and Clinical Research Committee		
Journal identification	Investigator	Work Group	Investigators	Investigators

AUTHORSHIP REQUIREMENTS

- Nominated individuals MUST be actively, and intellectually involved in the project to be a co-author.
- Authorship will be determined by the primary investigators for this project request, in alignment with these rules
- Co-authorship will only be warranted for collaborators who meet the ICMJE recommendations for authorship (<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>)
- The MaGIC Co-Chairs and Cooperative Group Chairs are not automatically co-authors, they will be co-authors only if they have been actively and intellectually involved in the project.
- To support the training goals of MaGIC, (full) professors are asked to consider co-senior authorship or not being senior author.

ACKNOWLEDGEMENT PARAGRAPHS

MaGIC Data Paper

Acknowledgments: The Malignant Germ Cell International Consortium and the Pediatric Cancer Data Commons are supported in part by the St. Baldrick's Foundation, the Rally Foundation for Childhood Cancer Research, Aflac Cancer and Blood Disorders Center, Children's Hospital of Atlanta and the Brantley Francis Foundation. This work is made possible through the efforts of the Children's Oncology Group COG, the Brazilian Society of Pediatric Oncology (SOBOPE), Clinical Research UK Clinical Trials Unit (CRCTU), the Medical Research Council (MRC), Fondazione IRCCS Istituto Nazionale dei Tumori, NRG Oncology, Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent (SFCE), Memorial Sloan-Kettering Cancer Center (MSKCC) Dana-Farber Cancer Institute (DFCI) and Tata Memorial Hospital.

MaGIC Consensus and Collaborative Paper

Acknowledgments: The Malignant Germ Cell International Consortium is supported in part by the St. Baldrick's Foundation, the Rally Foundation for Childhood Cancer Research, Aflac Cancer and Blood Disorders Center, Children's Hospital of Atlanta and the Brantley Francis Foundation.

MaGIC Grant Derived Paper

Acknowledgments: The Malignant Germ Cell International Consortium is supported in part by the St. Baldrick's Foundation, the Rally Foundation for Childhood Cancer Research, Aflac Cancer and Blood Disorders Center, Children's Hospital of Atlanta and the Brantley Francis Foundation.

(Please reach out to Lindsay.klosterkemper@dfci.harvard.edu if you have any questions on listed grants or require grant ID numbers).

TRACKING

The MaGIC Executive Committee will maintain a list of planned projects and manuscripts identified by all MaGIC Work Groups.

ABSTRACT AND MANUSCRIPT REVIEW PROCESS

The first and/or senior author will route the abstract and/or manuscript to the MaGIC Co-Chairs through Lindsay Klosterkemper (lindsay_klosterkemper@dfci.harvard.edu)

	MaGIC Data Paper	MaGIC Consensus Paper	MaGIC Collaborative Paper	MaGIC Grant Derived Paper
Abstract Review Required	Yes	Yes	No	Review rules are set by the Cooperative Groups (if applicable)
Manuscript Review Required	Yes	Yes	No	
Review Abstracts will be reviewed in five (5) business days Manuscripts will be reviewed in ten (10) business days	MaGIC Project Reviewers	MaGIC Executive Committee and Cooperative Group Chairs review: <input type="checkbox"/> A consensus paper reflected a true consensus of the groups and not just the expert opinions of the work group authors <input type="checkbox"/> Proper acknowledgments are included		
Feedback	The reviewers will provide feedback to the rest of the project team and work together with the rest of the team until the abstract or manuscript is ready.	The reviews will send comments to the authors and indicate <input type="checkbox"/> APPROVED <input type="checkbox"/> APPROVED with request that you consider the feedback <input type="checkbox"/> RE-REVIEW REQUESTED addressing the feedback		